Press Releases

Media Inquiries - media@caredxinc.com

Date	Title and Summary	Additional Formats
Toggle Summary Nov 26, 2018	CareDx Strengthens Executive Leadership Team with the Appointment of Reginald Seeto, MB.BS, as President and Chief Business Officer BRISBANE, Calif. , Nov. 26, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Reginald	View HTML
Toggle Summary Nov 26, 2018	CareDx Announces Full Repayment of its Outstanding Debt Recent Equity Financing Leads to Strong, Debt-Free Balance Sheet BRISBANE, Calif. , Nov. 26, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic	View HTML
Toggle Summary Nov 16, 2018	CareDx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares BRISBANE, Calif. , Nov. 16, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the closing of its	View HTML
Toggle Summary Nov 13, 2018	CareDx Announces Pricing of Public Offering of Common Stock BRISBANE, Calif. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the pricing of an	View HTML
Toggle Summary Nov 13, 2018	CareDx Announces Proposed Public Offering of Common Stock BRISBANE, Calif. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it intends to	View HTML
Toggle Summary Nov 08, 2018	CareDx Reports Third Quarter Results AlloSure launch momentum drives 74% revenue growth BRISBANE, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for	View HTML
Toggle Summary Nov 07, 2018	CareDx to Participate in Upcoming Investor Conferences BRISBANE, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag ,	View HTML
Toggle Summary Oct 17, 2018	CareDx to Announce Third Quarter 2018 Financial Results on November 8, 2018 BRISBANE, Calif. , Oct. 17, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release	View HTML
Toggle Summary Oct 02, 2018	CareDx Profiles AlloSeq Suite of NGS Products at ASHI Expands portfolio with three new kitted transplant products launching in 2019 Delivers new insights into the clinical Transplantome by incorporating HLA plus additional genes contributing to successful transplant outcomes Enables global access for laboratories to assess organ health by measuring	View HTML
Toggle Summary Sep 21, 2018	CareDx to Participate in Upcoming Investor Conference BRISBANE, Calif. , Sept. 21, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag ,	View HTML